Brazil has authorized clinical trials of the Indian Covid-19 vaccine against Covaxin – Prensa Latina

Projections indicate that 4,500 volunteers will take part in the tests: 3,000 in São Paulo and 500 in Rio de Janeiro, Bahia and Mato Grosso.

At the end of March, Anvisa refused a request to import 20 million doses of Covaxin into the national territory.

In April, Bharat Biotech stated that it has expanded its manufacturing capacity in various facilities to produce 700 million servings of the immune system annually.

The company indicated that it could expand in a short time thanks to the availability of the new BSL-3 specially designed facilities, the first of its kind for manufacturing in India.

He indicated that production partnerships are being explored in other countries with facilities that have previous experience in manufacturing inactivated viral vaccines on a commercial scale with containment of biosafety.

To increase capabilities, Bharat Biotech teamed up with Indian Immunologicals to develop the pharmaceutical substance Covaxin.

The CoronaVac vaccine from the Chinese Sinovac laboratory and produced by the Butantan Institute, corresponds to approximately 75 percent of the antigens applied in the national immunization program that has so far vaccinated 49.6 million Brazilians.

Brazil accumulates 430,417 lives and 15 million 433,989 infections due to the SARS-CoV-22 virus responsible for Covid-19.

jf / ocs / cvl

See also  Cuba is taking concrete measures to reverse the damage done to the global ecosystem

Leave a Reply

Your email address will not be published.